Current Management of Age-Related Macular Degeneration

Adv Exp Med Biol. 2021:1256:295-314. doi: 10.1007/978-3-030-66014-7_12.

Abstract

Age-related macular degeneration (AMD) remains a leading cause of blindness worldwide. The assessment and management of patients with this condition has evolved in the last decades. In this chapter, current standards for diagnosis, follow-up, and treatment of patients with AMD are reviewed and summarized. Namely, we highlight how current assessment has moved from conventional ophthalmoscopy and fluorescein angiography testing to a multimodal approach, and its important advantages. Alternatives to visual acuity for functional assessment of patients with AMD are also presented. Regarding strategies for follow-up and treatment, we provide specific information for the different stages (i.e., early, intermediate, and late) and forms (for example, choroidal neovascularization and geographic atrophy) of AMD. Specifically, we discuss the relevance and options for self-monitoring and non-pharmacological interventions. Additionally, a summary of the important trials (both on exudative and non-exudative AMD) that have helped inform clinical practice is provided, including data on antiangiogenic agents currently available, and outcomes of the different regimens that have been studied. The influence of advances in imaging on treatment strategies is also discussed.In summary, this chapter is a resource for all clinicians engaged in providing state of the art care for patients with AMD, and can help improve diagnosis, management, and outcomes of individuals with this blinding condition.

Keywords: Age-related macular degeneration; Choroidal neovascularization; Diagnosis; Disease management; Geographic atrophy; Intravitreal injections; Office visits; Optical coherence tomography; Photodynamic therapy; Visual acuity.

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use
  • Choroidal Neovascularization*
  • Fluorescein Angiography
  • Humans
  • Macular Degeneration* / drug therapy
  • Macular Degeneration* / therapy
  • Tomography, Optical Coherence

Substances

  • Angiogenesis Inhibitors